| 摘要 |
PURPOSE: To provide a method for treating or preventing nephrocalcinosis, nephrolithiasis and osteoporosis by decreasing the excretion of calcium by urine. CONSTITUTION: The above diseases can be cured by lowering the urinary calcium excretion by the administration of human or animal with a fatty acid composition containing (A)γ-linolenic acid(GLA) or dihomo-γ-linolenic acid(DGLA) as an essential component and (B) eicosapentaenoic acid(EPA), docosahexaenoic acid(DHA) or other essential fatty acids as arbitrary components. Preferably, the component A (especially GLA) is administered together with the component B (especially EPA and/or DHA) at a daily dose of 0.1-1,000mg/kg, preferably 0.1-50mg/kg, especially 2-30mg/kg each. The component A can be used as it is or in the form of a salt or other pharmacologically permissible compound and the component B is also usable as it is or in the form of other pharmacologically permissible compound.
|
